Status:
COMPLETED
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
Lead Sponsor:
Cephalon
Conditions:
Anxiety Disorders
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
Eligibility Criteria
Inclusion
- Subjects who have completed 10 weeks of double-blind treatment and the subsequent taper period in 1 of the 3 previous double-blind studies (studies C6671/3030/AX/US, C6671/3031/AX/US, or C6671/3032/AX/US).
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00214994
Start Date
January 1 2005
End Date
December 1 2006
Last Update
May 9 2014
Active Locations (93)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Research Group
Birmingham, Alabama, United States, 35216
2
Pivotal Research Center
Mesa, Arizona, United States, 85210
3
Pivotal Research
Peoria, Arizona, United States, 85381
4
Southwestern Research
Beverly Hills, California, United States, 90210